Deeptarup Biswas

Abstract Crosslinking mass spectrometry (XL-MS) is an exciting proteomics technology to capture native protein conformations in real time within biological systems. Historically, however, implementation of this technology has typically been limited to single purified recombinant proteins or in vitro assembled protein complexes.

1. Introduction Meningioma, the most common primary intracranial tumor, is predominantly slow-growing and known to arise primarily from arachnoid cap cells [1]. Meningioma has broadly been classified into 3 grades, majorly relying on histopathology and cytomorphological criteria. Grade I (benign) tumors comprise 95% of total meningioma cases, grade II (atypical) tumors comprise 4–5%, and, grade III (anaplastic) tumors comprising less than 1% are fast-growing malignant tumors [2].